

फा. सं. 15(4)/2020/Div. III/NPPA
Government of India/ भारत सरकार
Ministry of Chemicals & Fertilizers/ रसायन एवं उर्वरक मंत्रालय
Department of Pharmaceuticals/ औषध विभाग
National Pharmaceutical Pricing Authority/ राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण

3rd/ 5th Floor
YMCA Culture Centre Building
1, Jai Singh Road, N. Delhi-110001

Date: 24.07.2020

Office Memorandum

Subject: Availability of the Drug Clofazimine

Drug Clofazimine is a part of regimen for the treatment of MDR TB under National TB Elimination Program (NTEP) and there were references received from an advocacy group on shortage of Clofazimine, which falls under the scheduled drug list.

The matter regarding shortage/ non-availability of the drug was taken up by National Pharmaceutical Pricing Authority (NPPA) with Ministry of Health & Family Welfare (MoHFW). It has been confirmed by MoHFW that under NTEP they have continuous supply of Clofazimine and there are sufficient stocks in the pipeline for future consumption.

Also, no shortage/ non-availability of the drug has been reported by State Drug Controllers when asked in the matter.

Taking abundant caution and to ensure smooth production/ supply across the country of the drug, NPPA coordinated with the manufacturer and supplier Companies of the drug. The companies have also worked on to further streamline the production and supply of the drug to the private market. If still there are any instances of shortage/non-availability of the drug, the same may be brought to the notice of the Authority on **Helpline no 1800111255** and **e-mail id: monitoring-nppa@gov.in**.



(Pankaj Kumar)
Deputy Director

To: All State Drug Controllers (SDCs)

Copy for information to:

1. Drug Controller General (I)
2. Central TB Division, National TB Elimination Program (NTEP), Ministry of Health and Family Welfare